{"id":637,"date":"2020-11-09T10:25:05","date_gmt":"2020-11-09T10:25:05","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=637"},"modified":"2020-11-09T10:25:05","modified_gmt":"2020-11-09T10:25:05","slug":"04-nov-2020-azithromycin-nitazoxanide-ivermectin-and-hcq-azt-in-combination-with-drugs-proven-beneficial","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/04-nov-2020-azithromycin-nitazoxanide-ivermectin-and-hcq-azt-in-combination-with-drugs-proven-beneficial\/","title":{"rendered":"(04 Nov 2020) Azithromycin, Nitazoxanide, Ivermectin and HCQ- AZT in combination with drugs proven beneficial"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.31.20223883v1.full.pdf<\/p>\n<p class=\"\">The objective of the present study&nbsp; (NCT04446429) was to elucidate whether the conduction of a full placebo-control RCT was still ethically viable, through a comparative analysis with two control-groups. Compared to CG1 and CG2, AG showed a reduction of 31.5 to 36.5% in viral shedding (p &lt; 0.0001), 70 to 85% and 70 to 73% in duration of COVID-19 clinical symptoms when including and not including anosmia and ageusia, respectively ((p &lt; 0.0001 for both), and 100% in respiratory complications through the parameters of the Brescia COVID-19 Respiratory Scale (p &lt; 0.0001). For every 1,000 confirmed cases for COVID-19, a minimum of 140 patients were prevented from hospitalization (p &lt; 0.0001), 50 from mechanical ventilation, and five deaths, when comparing to age-, sex- and comorbidity-matched non-treated patients with similar initial disease severity at the moment of diagnosis. Compared to CG1 and CG2, AG showed a reduction of 31.5 to 36.5% in viral shedding (p &lt; 0.0001), 70 to 85% and 70 to 73% in duration of COVID-19 clinical symptoms when including and not including anosmia and ageusia, respectively ((p &lt; 0.0001 for both), and 100% in respiratory complications through the parameters of the Brescia COVID-19 Respiratory Scale (p &lt; 0.0001). For every 1,000 confirmed cases for COVID-19, a minimum of 140 patients were prevented from hospitalization (p &lt; 0.0001), 50 from mechanical ventilation, and five deaths, when comparing to age-, sex- and comorbidity-matched non-treated patients with similar initial disease severity at the moment of diagnosis.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.31.20223883v1.full.pdf The objective of the present study&nbsp; (NCT04446429) was to elucidate whether the conduction of a full&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/04-nov-2020-azithromycin-nitazoxanide-ivermectin-and-hcq-azt-in-combination-with-drugs-proven-beneficial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(04 Nov 2020) Azithromycin, Nitazoxanide, Ivermectin and HCQ- AZT in combination with drugs proven beneficial&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[82,6,4,9,16,85],"tags":[60,10,38,86],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/637"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=637"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/637\/revisions"}],"predecessor-version":[{"id":638,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/637\/revisions\/638"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}